Index

A

AADC. See Aromatic L–amino acid decarboxylase
AAV. See Adeno–associated virus
Abbvie, 91, 192
Abecma, 125
Abraham Lincoln’s DNA and Other Adventures in Genetics, 131
ACA. See Affordable Care Act
Acquired immunodeficiency syndrome (AIDS), xxiv, 6, 24–27, 41
Acute hepatic porphyria (AHP), 86
Adakveo, 143
Adderall, 89
Adeno–associated virus (AAV), 129–131, 133, 135–136, 196
Adenovirus vector, 130
ADHD. See Attention deficit hyperactivity disorder
Adrenoleukodystrophy (ALD), 123, 125
Aducanumab, 76
Afeyan, Noubar, 126
Affordability, orphan drugs
drug development costs, 184–187
one–time treatments, 194–196
overview, 9–10, 183–184
patient resources, 187–191
societal considerations, 191–194
Affordable Care Act (ACA), 9, 38, 187, 202
AHF. See Antihemophilic factor
AHP. See Acute hepatic porphyria
AIDS. See Acquired immunodeficiency syndrome
Alam, John, 79
Albers, Jeff, 51
ALD. See Adrenoleukodystrophy
Aldrich, Rich, 79, 162
Aldurazyme, 70–71, 194
Alexion, 76–78, 160
Alizé Pharma, 173–174
Alliance for Regenerative Medicine (ARM), 195
Allison, Jim, 121
Alynlam Pharmaceuticals, 73, 83–87, 132, 162
Alpha–1 antitrypsin deficiency, 83, 104
ALS. See Amyotrophic lateral sclerosis
Altschuler, Steve, 170
Alzheimer’s disease, xvi, 3–4, 76, 176
Amgen, xxiv, 35, 37, 69, 143
Amicus, 87–88
Amyloidosis transthyretin (ATTR), 69, 86
Amyotrophic lateral sclerosis (ALS), xiii, 161, 198, 206
Anand, Geeta, 45
Andersen, Terkel, 206
Angelman syndrome, 161
The Antidote, 79
Antihemophilic factor (AHF), 25
Antisense RNA, 75, 210
Antithrombin III (AT3), 97–98, 102–104
ARM. See Alliance for Regenerative Medicine
Aromatic L–amino acid decarboxylase (AADC), 133
Aspinall, Mara, 51
Astellas Pharmaceuticals, 172
AstraZeneca, 78, 128
Astrue, Michael, 6, 89, 162
AT3. See Antithrombin III
ATryn, 103–104
Attention deficit hyperactivity disorder (ADHD), 89
ATTR. See Amyloidosis transthyretin
Aubourg, Patrick, 123
## Index

Audentes, 171–172  
Aurora Biosciences, 80  
Auspitz, Ben, 149  
Avexis, 170–171  
Avigen, 133  
Avonex, 74

**B**

Bain and Company, xxv, 25  
Bamforth, Mark, 108, 169  
Bankiewicz, Krys, 132  
Bartel, David, 84  
Barton, Norm, 17  
Bartsch, Olaf, 58  
Batten’s disease, 71, 210  
Baxalta, 91–92  
Baxter, 24–28, 39, 91, 97, 122, 145, 162  
Baxter Travenol, 19–20, 32  
Beall, Bob, 80–82  
Béchon, Christian, 104  
Bell, Leonard, 76  
Bennett, Jean, 170  
Berman, Brian, 33–35  
Bernstein, Brad, 138  
Bespoke Gene Therapy Consortium (BGTC), 196  
Betaseron, 74  
BGTC. See Bespoke Gene Therapy Consortium  
Biden, Joe, 202  
Bienaimé, Jean–Jacques, 30, 71  
The Billion Dollar Molecule, 79  
BIO. See Biotechnology Innovation Organization  
BioCentury, 35  
Biogen, xxv, 16, 35, 72–78, 96, 128, 162, 171  
BioMarin, 29–30, 70, 162  
BioMatrix, 51  
BioSurface Technology, 50  
Biotechnology Innovation Organization (BIO), 87, 189–190  
BIO Ventures for Global Health (BVGH), 204–205  
Bioverativ, 75, 162  
Bird, Adrian, 139  
Blackrock, 205  
Blair, Henry, 19  
Blair, Tony, 15  
bluebird, 124–126, 194  
Boger, Josh, 78–79, 81  
Boice, Nicole, 197  
Bonney, Mike, 162  
Borgignon, Claudio, 146  
Boriero, Massimo, 58  
Bosley, Katrine, 162  
The Boy in the Plastic Bubble, 146  
Boyce, Nicole, 206  
Boyer, Herbert, 14, 16, 121  
Brady, Roscoe, 16–19, 31, 33, 35–36  
Brammer Bio, 169  
Broad Institute, 15, 138  
Burns, Jim, 51  
Butler, John, 51  
BVGH. See BIO Ventures for Global Health  

**C**

Califf, Robert, 168, 202  
California Institute of Regenerative Medicine (CIRM), 149  
Campath, 50  
Campbell, Bradley, 88  
CANbridge, 158–160  
CARD. See China Alliance for Rare Diseases  
Career Imprints: Creating Leaders across an Industry, xxvi  
Carpenter, Bob, 39, 96–97, 112  
CAR–T cell, 124–125  
Cartier, Nathalie, 123  
CBER. See Center for Biologics Evaluation and Research  
CCF. See Chinese Charitable Federation  
CDER. See Center for Drug Evaluation and Research  
Cedilla Therapeutics, 162  
Celgene, 69, 124  
Center for Biologics Evaluation and Research (CBER), 167, 169  
Center for Drug Evaluation and Research (CDER), 167  
Centronuclear myopathy (CNM), 174  
Ceredase, 36–40, 57, 59–61, 63  
CF. See Cystic fibrosis  
CFF. See Cystic Fibrosis Foundation

© 2022 by James A. Geraghty. Published by Cold Spring Harbor Laboratory Press. All rights reserved.
Chagas disease, 64
Chen, Y.T., 44
Cheng, Seng, 136
Chéreau, Fred, 51, 173
Chéreau, Fred, 51, 173
Cheresky, Marcelo, 64, 159
China
biotechnology overview, 4–5, 127, 155–156
CANbridge, 158–160
Genzyme interactions, 156–158
China Alliance for Rare Diseases (CARD), 159
Chinese Charitable Federation (CCF), 157
Chinoporos, Constantine, 110
CHMP. See Committee for Medicinal
Products for Human Use
Choudhury, Prithwiraj, 65
Christensen, Gustav, 91
Chronic lymphocytic leukemia (CLL), 50
Cinryze, 90
CIRM. See California Institute of
Regenerative Medicine
Clementia, 174
Clinical trials, costs, 185
Clinton, Bill, 15
CLL. See Chronic lymphocytic leukemia
CNM. See Centronuclear myopathy
The Code Breaker, 206
Coffre, Monica, 139–140
Cohen, Stanley, 14
Coles, Tony, 162
Collier, Duke, 37
Collins, Francis, 15
Collins, Michael, 84
Committee for Medicinal Products for
Human Use (CHMP), 152
Conscience and Courage: How Henri Termeer
Built a Biotech Giant and Pioneered the
Rare Disease Industry, xxvi, 31, 33
Cooney, Charlie, 31, 97
Cornu, François, 58–59
Corr, Bill, xx
Coughlin, Bob, 197
COVID-19, xvii, 84, 97, 126, 155, 168, 203
Cox, Geoff, 102
Cox, Gerry, 159
Cox, John, 162, 204
Cox, Tim, 39, 60
Creating Hope Act, 7
Crick, Francis, 14, 137
Crohn’s disease, 153
Crowley, John, 45, 87–88
Crowley, Megan, 45
Crowley, Patrick, 45
Creutzfeldt–Jacob disease, 28
Csimma, Zoltan, 49
Cubist Pharmaceuticals, 162
Cure Duchenne, 206
The Cure: How a Father Raised $100
Million—and Bucked the Medical
Establishment—In a Quest to Save His
Children, 45
Cure Rare Disease, 210
CXCR4, 174
Cystic fibrosis (CF), xiii, xv, xviii, 3, 47–48, 55, 69,
80–83, 101, 161
Cystic Fibrosis Foundation (CFF), 47,
80–83, 206

D
Dant, Jeanne, 70
Dant, Mark, 70
Dant, Ryan, 70–72
Daraprim, 186
Dasilva, Isabel Aznarez, 175
Davidson, Dave, 124
de Duve, Christian, 16–17
de la Tourette, George, xi
Denali Therapeutics, 126
Developing countries, orphan drug access,
203–205
DMD. See Duchenne muscular dystrophy
Doudna, Jennifer, 206
Douglas, Richard, 49
Dravet syndrome, 161, 175
Duchenne muscular dystrophy (DMD), xv, 3,
69, 163–167, 198, 202, 210
Dunoyer, Marc, 78
Dunsire, Deborah, 162
DUX–4, 140
Dyax, 91
Dyacure, 174
Dystrophin, 163, 166–167
Dzau, Victor, 112

E
Ebert, Karl, 98
Ebola, 8
Index

Echelard, Yann, 103
Eculizumab, 77
Editas Medicine, 126, 162
Elaprase, 90
e–Beshlawy, Amal, 66
El–Bialy, Mehat, 66
Eli Lily, 90, 120, 132
Ely, Robin, 34–35
EMA. See European Medicines Agency
ENCOD, 137
Enyedy, Mark, 51
Epogen, 37
EPPOSI. See European Platform for Patients
Organizations, Science and Industry
Erythropoietin, 89
Escape Bio, 175
Escherichia coli, 8
ESG investing, 205–206
Esiasion, Boomer, xiii
Eteplirsen, 164
Esiason, Boomer, xiii
EveryLife Foundation for Rare Diseases, 7, 145
Extraordinary Measures, 45

F

Fabrazyme, 42, 47, 61, 107–108
Fabry disease, 3, 17, 40, 42–43, 62, 66–67, 87
Facioscapulohumeral dystrophy (FSHD), xiv, 140–141
Factor VII, 104–105
Factor VIII, 21, 23–28, 30, 39, 89, 104
Factor IX, 21, 23, 104
FDA. See Food and Drug Administration
Feldbaum, Carl, 189–190
Fibrodysplasia ossificans progressiva
(FOP), 174
Fierce Biotech, 132, 138, 149
Finkel, Marion, xx
FioCruz, 64

Firazy, 90–91
Fire, Andrew, 83
Fischer, Alain, 146
Flagship, 126–127, 175, 211
Fleming, Dave, 156–157
Flotte, Terry, 84
Food and Drug Administration (FDA)
Abecma approval, 125
Aldurazyme approval, 70–71
Ceredase approval, 36
Fabrazyme approval, 42
Lumizyme approval, 46
Onpattro approval, 86
orphan drug approval, 2, 6
Patient–Focused Drug Development, 199
Sarepta interactions, 164–168
transfusion risk estimates for AIDS, 26
Food, Drug and Cosmetic Act, 6
FOP. See Fibrodysplasia ossificans
progressiva
Fobion, 127
Formela, Jean–Francois, 126
F–Prime Capital, 148–149
Fragile X syndrome (FXS), 140
Frates, Pete, xiii, 198
FRD. See Frontotemporal dementia
Friedman, John, 122
Frontotemporal dementia (FTD), 153
FSHD. See Facio–scapular–humoral
dystrophy
FTX–6058, 144
Fulcrum Therapeutics, 138–144
Furbish, Scott, 17
Furlong, Pat, 165–166, 198
FXS. See Fragile X syndrome

G

Galafold, 87–88
Galakatos, Nick, 86
Gao, Guangping, 131, 160
Gaspar, Bobby, 148, 150
Gates Foundation, 111, 204
Gaucher disease, 3, 17, 31, 33–40, 43, 47,
55, 60–64, 66–67, 108–109, 145,
156, 159
Gaucher, Philippe, xiii, 17
Gavin, Bill, 104
GBT. See Global Blood Therapeutics
Gelsinger, Jessie, 130, 147
GelTex Pharmaceuticals, 49
Gene editing, 209
Genentech, xxiv, 16, 121
Generation Bio, 173
Genetics Institute (GI), 27–28, 89
Genetix Pharmaceuticals, 121–126, 129
Genzyme Transgenics Corporation (GTC), 99–105
Gerety, Bob, 162
GI. See Genetics Institute
Gilbert, Walter, 72
Gilead, 69, 79
Givlaari, 86
GlaxoSmithKline (GSK), 87, 130, 140, 147, 149
Glaxo Wellcome, 79
Global Blood Therapeutics (GBT), 143–144
Global Genes, 7, 197, 206
Glucksman, Alexandra, 162
Goater, Jeff, 132
Goldberg, Mark, 159
Gordon, Katie, 96
Gottesdiener, Keith, 175
Gottleib, Scott, 169
Gould, Robert, 138
Graham, Bill, 19, 32, 39, 97
Gray, Mary Ann, 91
The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines, xxvi, 192
Green, Michael, 138
Greene, Barry, 86
Greenwood, Jim, 71, 189–190
Gregoire, Sylvie, 90
Gregory, Rich, 159
Groet, Suzanne, 159
Groff, Steve, 7
GSK. See GlaxoSmithKline
GTC. See Genzyme Transgenics Corporation

H

HA. See Hyaluronic acid
HAE. See Hereditary angioedema
Haffner, Marlene, 41

Hassan, Glenn, 159
Hastings, Paul, 57–58
Hatch, Orrin, xxii
Hawkins, John, xxvi, 31, 33, 162
Health Technology Assessment (HTA), 190–191
Heffernan, Jack, 49
Hematopoietic stem cell (HSC), 146, 153
Hemlibra, 29, 92, 204
Hemophilia, xv, 3, 20–29, 71–72, 75, 104–105, 204
Hempel, Chris, 174
Hempel, Hugh, 174
Hepatitis, 24, 26, 79–80
Hereditary angioedema (HAE), 69, 90–91
Hesslein, Bob, 110
Higgins, Michael, 134
Higgins, Monica, xxvi, 162
High, Kathy, 170
HIV. See Human immunodeficiency virus
Hoffman, Steve, 122
Homology Medicines, 162
Horgan, Rich, 210
Horowitz, Mia, 39
Howe, John, 156–157
HSC. See Hematopoietic stem cell
HTA. See Health Technology Assessment
Human Genome Project, 137
Human immunodeficiency virus (HIV), 23–26, 28, 79, 101
Humira, 101, 192–194
Huntingtin, 135
Huntington’s disease, xv, 135–136
Hyaluronic acid (HA), 50
Hydroxyurea, 142
Hyland Laboratories, 23

I

Icahn, Carl, 110
Ice Bucket Challenge, xiii, 198
ICER. See Institute for Clinical and Economic Review
IDEC Pharmaceuticals, 75
Iduronidase, 70
IG. See Integrated Genetics
Ilex Oncology, 50
Immunologic, 162
Incerti, Carlo, 61
Index

Incivek, 79
The Innovators, xxvi
Institute for Clinical and Economic Review (ICER), 82, 202
Institute for Life–Changing Medicines, 200
Insulin, 16
Integrated Genetics (IG), 39–40, 49, 96–98
International Pompe Association, 57, 206
Intron A, 72
In vitro fertilization (IVF), 210
Ionis Pharmaceuticals, 75
Ipsen, 174
Isaacson, Walter, xxvi, 206
IVF. See In vitro fertilization

J
Jaenisch, Rudolf, 138
Jerini AG, 90
Johnson, Malcolm, 58
Journey, 22

K
Kakkis, Emil, 69–71, 162
Kalydeco, 81–82
Kanuma, 78
Karen, xviii
Kay, Mark, 132, 172
Kaye, Ed, 164, 166, 175
Kefauver–Harris amendments, Food, Drug and Cosmetic Act, 6
Kennedy, Ted, xix, 3
Kennedy Shriver, Eunice, xviii
Kent, Alastair, 56
Kessler, David, 36
Khanna, Tarun, 65
Kids v Cancer, 7
Kilillea, Marie, xviii
Kinsella, Kevin, 79
Klugman, Jack, xx–xxii
Kohn, Donald, 149
Kolchinsky, Peter, xxvi, 189, 192
Kolodny, Ed, 17
Kowtunik, Walt, 138
Krainer, Adrian, 175
Kunkel, Lou, 163

L
Lander, Eric, 15, 121
Langer, Bob, 175
Lasagna, Louis, 6
LDL. See Low–density lipoprotein
LeBouilch, Philippe, 121
LeCam, Yann, 55
Lee, Jeannie, 138
Leiden, Jeff, 81
Lemtrada, 113
Leschly, Nick, 124
Levin, Mark, 119–120, 130–132, 138
Levy, Alberto, 63
Lewis, Jerry, xiii, xviii
LFB Group, 104
Libmeldy, 152
Lipitor, 14
Littlechild, John, 19
Lodish, Harvey, 31
LogicBio, 160, 172
London, Irving, 121
Looking the Tiger in the Eye: Confronting the Nuclear Threat, 189
Lorenzo’s Oil, 123
Losmapimod, 140
Love, Ted, 143
Low–density lipoprotein (LDL), 85
Lumizyme, 46–47
Luxturna, 170
Lysosomal acid lipase deficiency, 78

M
Mad cow disease, 28
Maderis, Gail, 51
Madison, Greg, 51
Malvilio, Fulvio, 146
Maniatis, Tom, 27
Marfan’s syndrome, 15
Marganore, John, 84–86, 162
Marks, Peter, 169, 210
Marrazzo, Jeff, 170
Martin, Craig, 197, 206
MassBio, 197
Massie, Robert, 22–23
Massie, Suzanne, 22
MC4R, 175
McDonough, Geoffrey, 51, 173, 204
McIntosh, David, 6
McKee, Blaine, 51
McLachlan, Dave, 49
McLaughlin, James, 130
McMurry–Heath, Michelle, 190
McNeill Laboratories, xii
McPhee, John, 161
Meade, Harry, 95–96, 98, 103
Meeker, David, 51, 114, 175
Meijer, Dick, 58
Mello, Craig, 83
Mendel, Jerry, 170
Merck, 85
Merieux, Alain, 36
Merrell, Ann, 51
Mersana Therapeutics, 162
Metachromic leukodystrophy (MLD), xiv, 69, 150–152
Methylmalonic acidemia (MMA), 161, 173
Metzenbaum, Howard, 38
Meyers, Abbey, xi–xiii, xx–xxi, 37, 67, 197, 206, 212
Meyers, David, xi–xii, xxi
Meyers, Jerry, xi–xiii, xxi
Meyers, Rachel, 86
Milano, Vin, 90
Milk, transgenic goat production of pharmaceuticals, 95–105
Millendo Therapeutics, 174
Millennium Pharmaceuticals, 120, 162
Milestone, George, 124
Mintz, Beatrice, 96
Mistry, Pram, 126
Monden, Walter, 63
More, Ginger, 19
Moreno, Jose, 104
Moscricki, Rich, 34
Mott, Dave, 126
MPS. See Mucopolysaccharidosis
MS. See Multiple sclerosis
Mucopolysaccharidosis (MPS), xiv, 66–67, 69–72, 148, 159, 194
Mueller, Peter, 79
Mulder, Geert–Jan, 122
Mullen, Jim, 75
Multiple sclerosis (MS), 50, 72–74, 101, 113
Murcko, Mark, 79
Muscular Dystrophy Association, 167
Myasthenia gravis, 101
Myozyme, 46–47, 62, 65, 108

N
Nader, François, 91
Naldini, Luigi, 146
Narasimhan, Vas, 171
National Center for Advancing Translational Sciences (NCATS), 7
National Gaucher Foundation (NGF), 34, 38, 206
National Hemophilia Foundation (NHF), 26
National Institute for Health and Clinical Excellence (NICE), 60, 152, 191
National Organization for Rare Disorders (NORD), xxiii, 37, 41, 67, 197, 206
NBS. See Newborn screening
NCATS. See National Center for Advancing Translational Sciences
Neglected tropical diseases (NTDs), 7
NEHI, 197
Nelsen, Bob, 126
Neufeld, Liz, 71
Neurocrine Biosciences, 134
New England Enzyme Center, 19
Newborn screening (NBS), 201
NGF. See National Gaucher Foundation
NHF. See National Hemophilia Foundation
NICE. See National Institute for Health and Clinical Excellence
Nicholas and Alexandra, 22
Nicholas II, 21
Niemann–Pick disease, 17, 174, 176
N of 1, 34–35, 209–210
No Patient Left Behind, 188
NORD. See National Organization for Rare Disorders
Novartis, 85, 136, 171, 194, 203
Novozyme, 44–45, 87
Noyes, Tim, 51
NPS Pharma, 91
NTDs. See Neglected tropical diseases

© 2022 by James A. Geraghty. Published by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Nuredis, 176
Nuvelo, 143

O
ODA. See Orphan Drug Act
ODD. See Orphan Drug Designation
Office of Rare Disease Research, 7
Office of Technology Assessment (OTA), 37–38
Ogier, Walter, 122
Onpatro, 86–87
Onyx Pharmaceuticals, 143, 162
Operation Warp Speed, 168
Orbimed, 171–172
Orchard Therapeutics, 148–149, 152–153
Orkambi, 82, 191
Ornithine transcarbamylase deficiency, 130
Orphan Drug Designation (ODD), 41, 161
Orphan Drugs: A Global Crusade, xxvii
Orphan Drugs and Rare Diseases, xxvii
Orphan: The Quest to Save Children with Rare Genetic Disorders, xv, xxvi, 13–14, 21, 131
Osteoporosis, 91
OTA. See Office of Technology Assessment
OvaScience, 162
Ovid Therapeutics, 175
Oxbryta, 143
Oxllumo, 86

P
Papadopoulos, Stelios, 51, 75, 99
PAPs. See Patient assistance programs
Parent Project Muscular Dystrophy, 165, 206
Parkinson’s disease, xvii, 132–134, 176
Paroxysmal nocturnal hemoglobinuria (PNH), 3, 69, 76–78, 160
Pasteur Merieux, 36
Pasteur, Alex, 149
Patent thicket, 192
Patient assistance programs (PAPs), 203
Patient–Focused Drug Development (PFDD), 199
Patrick, Deval, 32, 196, 197
Patterson, Matt, 171–172
Paul, Steve, 132
Personalized medicine, 209–210
PFDD. See Patient–Focused Drug Development
Pfizer, 30, 136
PGT. See Preconception genetic testing
PH1. See Primary hyperoxaluria type 1
Pharming, 44, 96
Phelps, Greg, 38
Phenylketonuria (PKU), 3, 15, 69, 71, 201
Pierce, Glenn, 204
PKD. See Polycystic kidney disease
PKU. See Phenylketonuria
Plump, Andy, 128
PNH. See Paroxysmal nocturnal hemoglobinuria
Policy innovation, importance in orphan drug development, 179–180
Pollack, Axel, 122
Polycystic kidney disease (PKD), xv
Pompe, Johannes, 43
Poole, Sandra, 108
Poortman, Ysbrand, 56
Possible Project, 120
PPL Therapeutics, 96, 100
Prader–Willi syndrome (PWS), 173
Preconception genetic testing (PGT), 211
Primary hyperoxaluria type 1 (PH1), 86
Priority review voucher (PRV), 6–7, 199–200
Pritchard, Amanda, 152
Progressive supranuclear palsy, 161
Project HOPE, 156–157
Protopapas, Anna, 162
PRV. See Priority review voucher
Ptashne, Mark, 27
PWS. See Prader–Willi syndrome

Q
Qasim, Waseem, 148
Queen Victoria, 21

R
Raab, Mike, 51
Ragan, Paula, 51, 174

© 2022 by James A. Geraghty. Published by Cold Spring Harbor Laboratory Press. All rights reserved.
Raptor Pharmaceuticals, 176
Rare Disease Day, 5, 56, 67
RARE Impact Award, 206
Rasputin, 21
Rathmann, George, 143
Ravina, Bernard, 132
RDLP. See Research and Development Limited Partnership
Reagan, Nancy, xxii–xxiii
Reagan, Ronald, xxii–xxiii, 3
Recombinate, 28
Redux–4 trial, 141
Regeneron, 69
Reilly, Phil, xv, xxvi, 13–15, 21, 25, 130–132, 138
Reinberg, Danny, 138
Relapse–remitting multiple sclerosis (RRMS), 3, 74
Renagel, 49, 51, 61
Replagal, 42–43, 61
Research and Development Limited Partnership (RDLP), 48
Rett syndrome, xv, 138–140
Rett Syndrome Research Trust (RSRT), 139
Reuser, Arnold, 44
Rhythm Pharmaceuticals, 175
Ridley, David, 6
RNA interference, 83–87
Roberts, Bruce, 96
Roche, 16, 29, 170, 204
Romanov, Alexsei, 21
Romney, Mitt, xxv, 197
Roslin Institute, 100
Rothera, Mark, 149
Royo, Fernando, 58
RPE65, 170
RRMS. See Relapse–remitting multiple sclerosis
RSRT. See Rett Syndrome Research Trust
Russell, Angus, 90
Ryan Foundation, 70

S

Sah, Dinah, 86, 132
Sahney, Sandeep, 65
Sandrock, Al, 74, 136
Sangamo, 30
Sanger, Frederick, 14
Sangstat, 49–50
Sanofi, 111–115, 124, 128, 133–134, 156–158
Sarepta Therapeutics, 163–167, 201
Sato, Vicki, 79, 162
Scangos, George, 75, 204
SCD. See Sickle cell disease
Schering–Plough, 72
Schikan, Hans, 57
Schimmel, Paul, 84
Schmorgan, Gabriel, 27–28
Schneider–Mergener, Jens, 90
Schoneveld van der Linde, Maryze, 56–57
SCID. See Severe combined immunodeficiency
Secor, Alicia, 51
Seligman, Muriel, xix
Seprafilm, 50
Sevenfact, 104–105
Severe combined immunodeficiency (SCID), 146–153
Shapiro, Arthur, xii
Sharp, Phil, 72–73, 84
Sherblom, Jim, 49
Shire Pharmaceuticals, 87, 89–92, 128
Shkreli, Martin, 186–187
Sickle cell disease (SCD), xv, 3, 15, 83, 121, 123, 141–144
Sigilon Therapeutics, 175
Silverstein, Jonathan, 171
Simonian, Nancy, 162
Sirna Therapeutics, 85
Slanetz, Alfred, 122
SMA. See Spinal muscular atrophy
Smith, Alan, 96
Smith, Cees, 56
Smith, Julie Anne, 51, 175–176
Smith, Sandy, 57
Smith, Tom, 99
Snyder, Richard, 169
Snyder, Sherry, 19
Soliris, 77–78
Solvadi, 79–80
A Song in the Night: A Memoir of Resilience, 23
Soteropoulos, Paula, 51
Spark Therapeutics, 29, 170
Special Olympics, xviii
Specter, Arlen, 190

© 2022 by James A. Geraghty. Published by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Spezzi, Andrea, 149
Spinal muscular atrophy (SMA), 69, 72, 75, 170–171, 194, 203
Spinocerebellar ataxia, 161
Spinraza, 75, 171, 175
Squinto, Stephen, 76
Stahel, Rolf, 89
Starr, Kevin, 120
Stoke Therapeutics, 175
Stölzle, Ute, 58, 60
Strimvelis, 147, 149–150
Stuart, Bryan, 144
Suhr, Dean, 151
Suhr, Lindy, 151
Suhr, Teryn, 151
Sulston, John, 15
Swanson, Bob, 16, 121
Symdeko, 82
Syntonix Pharmaceuticals, 75
Sulist, 51
Syros Pharmaceuticals, 162

T
Tagamet, 13
Takeda, 66, 92, 120, 128
Tambuyzer, Erik, 55
Tecfidera, 74
Telethon Institute for Gene Therapy (TIGET), 146–147
Tepper, Bob, 120
Termeer, Belinda, 114
Thalassemia, 15, 83, 121, 123–124, 194
Thalidomide, 6
The Medicines Company (TMC), 85
Thermo Fisher, 169
Thomas, Frank, 149
Thrasher, Adrian, 148
Thymoglobulin, 49–50
Thyrogen, 49, 61
Tierney, Tomye, 156–157
TIGET. See Telethon Institute for Gene Therapy
TKT. See Transkaryotic Therapies
TMC. See The Medicines Company
Tobin, Jim, 73
Tourette’s syndrome, xi–xiii
Transkaryotic Therapies (TKT), 42–44, 61–62, 89–90, 162
Transthyretin amyloidosis. See Amyloidosis transthyretin
Travenol, 19, 32
TRV. See Third Rock Ventures
Tung, Roger, 162
Turenne, Andre, 134
Turing Pharmaceuticals, 186
Turner, Frederic, 59
Tuschi, Tom, 57
21st Century Cures Act, 7
Tysabri, 74
Tzianabos, Arthur, 162

U
Ultragenyx, 162
Usdin, Steve, 35

V
Vaishnaw, Akshay, 86
Values, importance in orphan drug development, 177–179
van der Ploeg, Ans, 44
van Heek, Christi, 38
van Heek, Jan, 38, 57
van Rooijen, Stéphane, 51, 174
Varmus, Harold, 111
Vertex, 78–83, 162, 191
Viehbacher, Chris, 111–114
Vincent, Jim, 73
ViroPharma, 90–91
Vivaldi, Rogerio, 51, 63, 175
Vos, Alexander, 51
Vounatsos, Michel, 75
Voyager Therapeutics, 131–136, 138

W
Walsh, Jeff, 124
Warren, Earl, 3
Index 265

Watson, James, 14, 137
Waxman, Henry, xix–xxiii, 2–4
Webber, Chris, 128
Weissman, Charles, 72
Werth, Barry, 79
WFH. See World Federation of Hemophilia
WHIM syndrome, 161, 174–175
White, Ryan, 26
Whitesides, George, 31
Whitworth, Ralph, 110
Wilson, Jim, 48, 88, 130, 200
Wirth, Peter, 49, 112
Wood, Joan, 49
Woodcock, Janet, 167–168, 210
World Economic Forum, 112
World Federation of Hemophilia (WFH), 204
WuXi Biologics, 159
Wyzga, Mike, 49

X
X4 Pharmaceuticals, 174
X–linked adrenoleukodystrophy, 161
X–linked myotubular myopathy (XLMTM), 171–172
XLMTM. See X–linked myotubular myopathy
Xue, James, 51

Y
Yamada, Tachi, 130, 200
Young, Mike, 102
Yu, Timothy, 210

Z
Zafgen, 173
Zamore, Phil, 84, 131–132
Zantac, 13
Zelig, Ze’ev, 63
Zerhouni, Elias, 18, 111–112, 114, 128
Zimran, Ari, 63
Zolgensma, 170–171, 203
Zynteglo, 125